Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Keenova Therapeutics plc

Life Sciences · 6 alerts · CIK 1567892

Shares outstanding
39.65MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Keenova Therapeutics plc filings on SEC EDGAR ↗

4:31 PM ET Form 4
Insider Buying

Keenova Therapeutics Insider Goldentree Asset Management LP Buys $13.7M of Stock

Goldentree Asset Management LP bought 150,652 shares of Keenova Therapeutics plc at $89.25 to $91.00 a share (average $90.65) in 2 transactions, worth $13.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 9,026,195 (+1.4%).

Value
$13.7M
Shares
150,652
Average price
$90.65
Holding change
+1.4%
Trade date
Nov 9, 2026 to Nov 10, 2026
5:15 PM ET 10-Q
Financial Results

Keenova Therapeutics Q3 2026 Results: Net Loss of $96.1M, Loss Narrows

Keenova Therapeutics reported net sales of $549.5 million for the quarter ended September 30, 2026, a significant increase from $416.1 million in the prior year. Despite higher revenue, the company recorded a net loss of $96.1 million for the quarter and $430.1 million for the nine-month period, primarily driven by a $150.6 million loss on divestiture and $207.7 million in non-restructuring impairment charges.

Key figure
Net loss $96.1M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.